Shay L E, Thomas R V, Wyvill K M, Adamo D O, Jenkins J F
Medicine Branch, NCI, NIH, Bethesda, Maryland 20892.
Cancer Nurs. 1990 Oct;13(5):269-77.
2',3'-Dideoxyinosine (ddI) is a dideoxynucleoside currently in Phase I, II, and III trials for antiretroviral therapy. It has been shown to cause objective and subjective improvement in people with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC). This drug, as with any drug, is not without toxicity. Through thorough patient education and clinical evaluation, incidence of these toxicities may be lessened or avoided.
2',3'-双脱氧肌苷（ddI）是一种双脱氧核苷，目前正处于抗逆转录病毒治疗的I期、II期和III期试验阶段。已证明它能使获得性免疫缺陷综合征（AIDS）和艾滋病相关综合征（ARC）患者在客观和主观上得到改善。与任何药物一样，这种药物也并非没有毒性。通过全面的患者教育和临床评估，这些毒性的发生率可能会降低或避免。
